When was Genmab founded?

Genmab was founded in 1999 and raised its 1st funding round 10 years after it was founded.

Where is Genmab located?

Genmab is headquartered in Copenhagen, Denmark. It is registered at Princeton, New Jersey.

Who is the current CEO of Genmab?

Jan van de Winkel of Genmab. They have also founded 1 company.

How many employees does Genmab have?

As of Sep 30, 2026, the latest employee count at Genmab is 3081.

Is Genmab a funded company?

Genmab is a funded company, having raised an undisclosed amount across 3 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Oct 01, 2009.

When was the latest funding round of Genmab?

Genmab's latest funding was a $***** Post IPO round on Jan 23, 2014, with participation from 0 investor.

Where does Genmab rank among its competitors?

Genmab ranks 221st amongst 3352 active competitors, of which 1130 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Genmab?

Genmab's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Genmab - 2026 Company Profile, Team, Funding, Competitors & Financials

Genmab is a public company based in Copenhagen (Denmark), founded in 1999 by Jan van de Winkel. It operates as a Developer of antibody therapeutics for the treatment of cancer and autoimmune diseases. Genmab has raised an undisclosed amount in funding. The company has 3352 active competitors, including 1130 funded and 785 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of antibody therapeutics for the treatment of cancer and autoimmune diseases. The company uses proprietary DuoBody, HexaBody, DuoHexaBody, and HexElect technologies, to harness the power of human antibodies to develop a robust pipeline of products such as Teprotumumab for thyroid eye disease, Tisotumab vedotin for solid and cervical cancer, Darzalex for multiple myeloma, and more.

Website: www.genmab.com/
Registered Address: Princeton, New Jersey

Key Metrics

Founded Year

1999

Location

Copenhagen, Denmark

Stage

Public

Latest Funding Round

Post IPO, Jan 23, 2014, $*****

Investors

HBM Healthcare Investments & 3 more

Ranked

221^st among 3352 active competitors

Employee Count

3,081 as on Sep 30, 2026

Investment & Acquisitions

Merus & 2 more

Similar Companies

Jazz Pharmaceuticals & 3054 more

Exit Details

Public

View Genmab's full profile

Genmab is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Genmab A/s CIN: 21023884 , Denmark, Active	Jun 10, 1998	-	567 (As on Mar 31, 2024)
GENMAB US, INC. CIN: 262011084 , United States, Active	Dec 26, 999	-	1067 (As on Dec 31, 2024)	-

Genmab got listed on Oct 20, 2000.

Click here to take a look at Genmab's IPO in detail

Genmab has raised funding over 3 rounds. Its first funding round was on Oct 01, 2009. Genmab has 4 institutional investors.

Here is the list of recent funding rounds of Genmab:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 23, 2014	6435428	Post IPO	2138569	1546707	9019944	1492320
Jul 01, 2010	7043510	Post IPO	4076301	8805288	1112982	9322564
Oct 01, 2009	1552283	Post IPO	7849821	6650208	4505739	GSK

Access funding benchmarks and valuations. Sign up today!

View details of Genmab's funding rounds and investors

The founders of Genmab is Jan van de Winkel. Jan van de Winkel is the CEO of Genmab.

Here are the details of Genmab's key team members:

Jan van de Winkel: Co-Founder & CEO of Genmab and founder of 1 other company.

View details of Genmab's Founder profiles and Board Members

Genmab's employee count trend

Genmab has 3,081 employees as of Sep 26. Here is Genmab's employee count trend over the years:

Uncover Genmab's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Genmab include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Genmab, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
221st	Genmab 1999, Copenhagen (Denmark), Public	Developer of antibody therapeutics for the treatment of cancer and autoimmune diseases	-	HBM Healthcare Investments, NB Capital & 2 others	61/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Genmab's competitors? Click here to see the top ones

Genmab has made 1 investment in Paradigm Therapeutics and acquired Merus and Profound Bio.

Here is the list of these investments and acquisitions:

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Dec 12, 2025	Acquisition	Merus	2003	Utrecht (Netherlands)
Apr 03, 2024	Acquisition	Profound Bio	2018	Woodinville (United States)
Dec 09, 2002	Investments	Paradigm Therapeutics	1999	Cambridge (United Kingdom)